Ovarian function suppression

Ovarian function suppression has been studied in 5 papers since 2024: 3 observational studies in people, 2 reviews; 4 in the past year. The newest paper, Nov 20, 2026: “Estrogen loss and Alzheimer’s disease: five exposures ordered by age, and why timing is the variable to test”.

Exposure

5 papers study it1 findingUpdated

4 new papers in 30 daysSee all 5 papers on ovarian function suppression

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“the tamoxifen plus OFS group had lower baseline MRS scores but higher scores at 6 and 12 months”
Menopausal Symptom Burden in Premenopausal Breast Cancer Patients: Interaction of Chemotherapy and Ovarian Function Suppression on Tamoxifen TreatmentClinical breast cancer2024doi:10.1016/j.clbc.2024.12.007
Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funders: Kangwon National University and 2 more
  • Humans3

What is ovarian function suppression linked with?

1

Studies link ovarian function suppression with menopausal symptom burden.

Menopausal symptom burden

upin humans1

1 study
  1. Ovarian function suppression is associated with menopausal symptom burden in humans (Estimate 6.084; standard error 1.306; P < .001).

    HumansPremenopausal patients with breast cancer taking tamoxifen; comparison with tamoxifen alone6 monthsn = 209

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 2Nov 2026: 24 papers in 12 months